-
公开(公告)号：US07553483B2
公开(公告)日：2009-06-30
申请号：US10499100
申请日：2002-12-16
CPC分类号： C07K14/523 , A61K38/00
摘要： Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
摘要翻译： 在保守的共有序列中含有非保守取代的特异性CC-趋化因子的突变体作为CC-趋化因子拮抗剂，可以有效地用于治疗自身免疫性和炎性疾病，癌症和病毒或细菌感染。 特别优选的是具有SEQ ID NO：1,2,3或4的氨基酸序列的RANTES / CCL5突变体。
-
公开(公告)号：US20050220757A1
公开(公告)日：2005-10-06
申请号：US10499100
申请日：2002-12-16
IPC分类号： C12N15/09 , A61K38/00 , A61K38/19 , A61K45/00 , A61P29/00 , A61P31/04 , A61P31/12 , A61P35/00 , A61P37/06 , C07K14/47 , C07K14/52 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/19 , C12P21/02
CPC分类号： C07K14/523 , A61K38/00
摘要： Mutants of specific CC-chemokines containing a non-conservative substitution in a conserved consensus sequence act as CC-chemokine antagonists, and can be effectively used in the treatment of autoimmune and inflammatory diseases, cancers, and viral or bacterial infections. Particularly preferred are the RANTES/CCL5 mutants having the amino acid sequence of SEQ ID NO: 1, 2, 3, or 4.
摘要翻译： 在保守的共有序列中含有非保守取代的特异性CC-趋化因子的突变体作为CC-趋化因子拮抗剂，可以有效地用于治疗自身免疫性和炎性疾病，癌症和病毒或细菌感染。 特别优选的是具有SEQ ID NO：1,2,3或4的氨基酸序列的RANTES / CCL5突变体。
-
公开(公告)号：US20070004906A1
公开(公告)日：2007-01-04
申请号：US10510658
申请日：2003-04-09
CPC分类号： C07K14/523 , A61K38/00
摘要： Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.
摘要翻译： MCP蛋白特别是MCP-1蛋白的新型拮抗剂可以通过产生MCP突变体获得，其MCP位点位于MCP蛋白的N-末端，其在非保守取代之后被消除。 根据本发明制备的化合物可用于治疗或预防与MCP蛋白质不期望的活性相关的疾病，例如炎性疾病，自身免疫性疾病，血管疾病和癌症。
-
公开(公告)号：US07425324B2
公开(公告)日：2008-09-16
申请号：US10510658
申请日：2003-04-09
CPC分类号： C07K14/523 , A61K38/00
摘要： Novel antagonists of MCP proteins, in particular of MCP-1 protein, can be obtained by generating MCP mutants whose GAG binding site, located at the N-terminal of MCP proteins, is eliminated following non-conservative substitutions. Compounds prepared in accordance with the present invention can be used in the treatment or prevention of diseases related to an undesirable activity of MCP proteins such, such as inflammatory disease, autoimmune diseases, vascular diseases, and cancer.
摘要翻译： MCP蛋白特别是MCP-1蛋白的新型拮抗剂可以通过产生MCP突变体获得，其MCP位点位于MCP蛋白的N-末端，其在非保守取代之后被消除。 根据本发明制备的化合物可用于治疗或预防与MCP蛋白质不期望的活性相关的疾病，例如炎性疾病，自身免疫性疾病，血管疾病和癌症。
-
公开(公告)号：US20050220759A1
公开(公告)日：2005-10-06
申请号：US10510014
申请日：2003-03-31
IPC分类号： A61K38/00 , A61K38/19 , A61P25/00 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/12 , A61P37/00 , A61P37/02 , C07K14/47
CPC分类号： A61K38/195
摘要： The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1β, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.
摘要翻译： 通过以非保守的方式代替二元位点中的至少一个残基，改善了含有二十一位点在40位保守阳离子序列（如RANTES和MIP-1beta）中的C-C趋化因子的口服功效。
-
公开(公告)号：US07402303B2
公开(公告)日：2008-07-22
申请号：US10398457
申请日：2001-10-03
CPC分类号： C07K14/523 , A61K38/00
摘要： Mutants of CC chemokines, which contain at least two mutations in the cationic site of the 40's loop and which, relative to the wild-type molecule, have a reduced GAG-binding activity. In particular it has been found that such mutated chemokines are effective in the treatment of multiple sclerosis and/or demyelinating diseases. A triple mutant of RANTES is the compound showing the best results.
摘要翻译： CC趋化因子的突变体，其在40个环的阳离子位点含有至少两个突变，相对于野生型分子具有降低的GAG结合活性。 特别地已经发现，这种突变趋化因子在多发性硬化症和/或脱髓鞘疾病的治疗中是有效的。 RANTES的三重突变体是显示最好结果的化合物。
-
公开(公告)号：US07541435B2
公开(公告)日：2009-06-02
申请号：US10517726
申请日：2003-06-03
CPC分类号： C07K14/522 , A61K38/00
摘要： Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3-expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.
摘要翻译： CXCR3结合CXC趋化因子，特别是人CXCL11的新型拮抗剂可以通过产生这样的趋化因子的突变体来获得，其中与糖胺聚糖（GAG）的结合由于涉及该相互作用的氨基酸的非保守取代而受损。 根据本发明制备的化合物可用于阻断CXCR3结合CXC趋化因子对CXCR3表达细胞的活性，从而提供用于治疗或预防与过度活化的T细胞迁移有关的疾病的治疗组合物，例如 移植排斥反应和自身免疫性疾病以及需要增加血管形成的疾病，如缺血性心脏病。
-
公开(公告)号：US07335350B2
公开(公告)日：2008-02-26
申请号：US10510014
申请日：2003-03-31
CPC分类号： A61K38/195
摘要： The oral efficacy of C—C chemokines containing a dibasic site in the 40's conserved cationic sequence, such as RANTES and MIP-1β, is improved by substituting at least one of the residues in the dibasic site in a non-conservative manner.
摘要翻译： 通过以非保守的方式代替二元位点中的至少一个残基，改善了含有二十一位点在40位保守阳离子序列（如RANTES和MIP-1beta）中的C-C趋化因子的口服功效。
-
公开(公告)号：US20060204498A1
公开(公告)日：2006-09-14
申请号：US10517726
申请日：2003-06-03
IPC分类号： A61K39/395 , C07H21/04 , C12P21/06 , C07K16/24
CPC分类号： C07K14/522 , A61K38/00
摘要： Novel antagonists of CXCR3-binding CXC chemokines, and in particular of human CXCL11, can be obtained by generating mutants of such chemokines in which the binding to glycosaminoglycans (GAGs) is impaired due to non-conservative substitutions of amino acids involved in this interaction. Compounds prepared in accordance with the present invention can be used to block the activity of CXCR3-binding CXC chemokines on CXCR3-expressing cells, thereby providing therapeutic compositions for use in the treatment or prevention of diseases related to excessive activated T cells migration, such as graft rejection and autoimmune diseases, and of diseases needing an increase of vascularization, such as ischemic heart disease.
摘要翻译： CXCR3结合CXC趋化因子，特别是人CXCL11的新型拮抗剂可以通过产生这样的趋化因子的突变体来获得，其中与糖胺聚糖（GAG）的结合由于涉及该相互作用的氨基酸的非保守取代而受损。 根据本发明制备的化合物可用于阻断CXCR3结合CXC趋化因子对CXCR3表达细胞的活性，从而提供用于治疗或预防与过度活化的T细胞迁移有关的疾病的治疗组合物，例如 移植排斥反应和自身免疫性疾病以及需要增加血管形成的疾病，如缺血性心脏病。
-
公开(公告)号：US07740833B2
公开(公告)日：2010-06-22
申请号：US10573625
申请日：2004-10-18
申请人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
发明人： Amanda Proudfoot , Jeffrey Shaw , Zoe Johnson
CPC分类号： C07K14/523 , A61K38/00 , C07K2319/30 , G01N33/6863 , G01N2500/00 , G01N2800/24 , G01N2800/285
摘要： Variants of homodimer-forming chemokines, such as human CCL2, having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds and acting as an obligate monomer, can antagonize natural chemokines and have anti-inflammatory activity in vivo. These variants can be used as active ingredient in pharmaceutical compositions for the treatment of inflammatory, autoimmune, or infectious diseases.
摘要翻译： 在二聚化界面中具有改变氢键图案和作为专性单体的单一氨基酸取代的同源二聚体形成趋化因子（例如人CCL2）的变体可以拮抗天然趋化因子并且在体内具有抗炎活性。 这些变体可用作用于治疗炎性，自身免疫性或感染性疾病的药物组合物中的活性成分。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.021 秒)
